Toujeo® Reduces Risk of Hypoglycemia in Older Adults With Type 2 Diabetes
Sanofi announced new evidence from a real-world observational study demonstrating significantly less risk of documented hypoglycemia with similar blood sugar control after switching to Toujeo® (insulin glargine 300 units/mL) compared to switching to another basal insulin, including Lantus® (insulin glargine 100 units/mL), Levemir® (insulin detemir), and Tresiba® (insulin degludec), in an at-risk population of 1,610 older adults with type 2 diabetes.
The DELIVER program comprises several non-interventional, retrospective analyses using data from the Predictive Health Intelligence Environment database of U.S. real-world electronic medical records, currently representing 37 integrated health delivery networks. Hypoglycemia was identified in the dataset by diagnosis code or plasma glucose (≤70 mg/dL by laboratory test).
In the DELIVER 3 study, patients switching to Toujeo were 57% less likely to experience hypoglycemia at 6-month follow up (odds ratio = 0.432, 95% confidence interval [0.307, 0.607], p < 0.0001) than those who switched to another basal insulin. Switching to Toujeo or another basal insulin resulted in comparable changes in HbA1c (least squares mean difference = −0.09%, p = 0.24).
These findings are broadly consistent with Toujeo evidence from DELIVER 2, a retrospective observational study that included two matched cohorts of 1,827 adults (N = 3,654) with type 2 diabetes using basal insulin who switched to either Toujeo or another basal insulin. DELIVER 2 demonstrated 33% fewer hypoglycemic events in patients after 6 months, which contributed to an estimate of all-cause health care cost savings of approximately $2,000 per patient per year.
Source.“In Senior Adults Treated With Basal Insulin, Switching to Sanofi's Toujeo®Halved Hypoglycemia Risk.” (2017, June 10). Retrieved June 28, 2017, from http://prn.to/2sUNmbt.
Color Your Mind Connects Coloring With Wellness and Brain Health for Individuals With Alzheimer's Disease
Blue Star Coloring has taken its mission to inspire wellness through creative expression to a new level with Color Your Mind: A Coloring Book for Those with Alzheimer's and the People Who Love Them, authored by award-winning journalist, best-selling author, and Alzheimer's disease advocate Maria Shriver.
Shriver and Blue Star Press sought the expertise of physicians, caregiving professionals in memory care facilities, and individuals diagnosed with Alzheimer's disease as they developed artwork and activities. Coloring pages in the book are found alongside activity suggestions and prompts for shared reflection and conversation. Color Your Mind is entirely unique in that it connects coloring with information surrounding wellness and brain health, social connection, nutrition, exercise, and more.
Source.“Imagine a World Without Alzheimer's: Book by Maria Shriver and Blue Star Press.” (2017, June 6). Retrieved June 28, 2017, from http://prn.to/2tm5uvf.